PRINCETON, N.J. / Dec 06, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on February 1, 2024, to stockholders of record at the close of business on January 5, 2024.
This quarterly dividend represents a 5.3% increase over last year’s quarterly rate of fifty-seven cents ($0.57) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2024 is $2.40 per share. This marks the 15th consecutive year that the company has increased its dividend and the 92nd consecutive year that the company has paid a dividend.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 1, 2024, to stockholders of record at the close of business on January 30, 2024.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Last Trade: | US$50.36 |
Daily Change: | -0.98 -1.91 |
Daily Volume: | 3,269,089 |
Market Cap: | US$102.230B |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load